162011-83-8

Basic information

• Product Name: 3-(3,4-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5H)-furanone
• Synonyms: 3-(3,4-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5H)-furanone;4-(3,4-difluorophenyl)-3-(4-methylsulfonylphenyl)-2H-furan-5-one
• CAS NO: 162011-83-8
• Molecular Formula: C₁₇H₁₂F₂O₄S
• Molecular Weight: 350.3366
• Mol File: 162011-83-8.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 575.8°Cat760mmHg
• Flash Point: 302°C
• Appearance: /
• Density: 1.435g/cm³
• Vapor Pressure: 2.94E-13mmHg at 25°C
• Refractive Index: 1.594
• CAS DataBase Reference: 3-(3,4-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5H)-furanone(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(3,4-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5H)-furanone(162011-83-8)
• EPA Substance Registry System: 3-(3,4-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5H)-furanone(162011-83-8)

Safety Data

• Hazardous Substances Data: 162011-83-8(Hazardous Substances Data)

Usage

InChI:InChI=1/C17H12F2O4S/c1-24(21,22)12-5-2-10(3-6-12)13-9-23-17(20)16(13)11-4-7-14(18)15(19)8-11/h2-8H,9H2,1H3

Upstream product

• 658-93-5 (3,4-difluorophenyl)acetic acid 
• 50413-24-6 2-bromo-1-(4-methanesulfonylphenyl)ethanone 
• 121-44-8 triethylamine 

Downstream Products

• 179174-83-5 (2Z)-4-(acetoxy)-2-(3,4-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]but-2-enoic acid 
• 179174-80-2 (2Z)-2-(3,4-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]but-2-ene-1,4-diol 
• 179174-82-4 (Z)-4-acetoxy-3-(4-(methylsulfonyl)phenyl)-2-(3,4-difluorophenyl)-2-butenal 
• 179174-81-3 (2Z)-3-(3,4-difluorophenyl)-4-hydroxy-2-[4-(methylsulfonyl)phenyl]but-2-en-1-yl acetate 
• 851609-10-4 2-(3,4-difluoro-phenyl)-3-(4-methanesulfonyl-phenyl)-but-2-ene-1,4-diol 

Relevant articles and documents

Water soluble prodrug of a COX-2 selective inhibitor suitable for intravenous administration in models of cerebral ischemia

A water soluble choline prodrug (17) of a COX-2 selective inhibitor (16) suitable for intravenous dosing in models of cerebral ischemia has been developed. Constant infusion studies using 17 demonstrate that extrapolated brain levels of 16 may be maintained for over 24 h in rats.

Method of treating cancer

The present invention relates to methods of treating cancer using a combination of a compound which is a PSA conjugate and an NSAID compound, which methods comprise administering to said mammal, either sequentially in any order or simultaneously, amounts of at least two therapeutic agents selected from a group consisting of a compound which is a PSA conjugate and an NSAID compound. The invention also relates to methods of preparing such compositions.

Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor

Treatment with a cyclooxygenase-2 inhibitor and a leukotriene A4hydrolase inhibitor is described as being useful in reducing recipient rejection of transplanted organs and for treatment of autoimmnune diseases.